Shots:
- The P-III trial evaluates arpraziquantel in patients aged 3mos. to 6yrs. with schistosomiasis who are infected with S. mansoni or S. haematobium
- The trial has met its 1EPs i.e., the therapy showed high efficacy with 90% cure rates for S. mansoni (50 mg/kg) & S. haematobium (at a dose of 60 mg/kg), favorable safety, tolerability & improved palatability among children at both doses with no new risks or safety concerns
- The company plans to submit a regulatory filing to the EMA. The therapy is safe, effective & suitable for children& adults which was developed by Astellas in Japan, optimized by Merck in Germany & transferred for clinical manufacturing to Farmanguinhos in Brazil
Click here to read the full press release/ article | Ref: Merck | Image: Spagnola & Associates
The post Merck Reports Results of Arpraziquante in P-III Clinical Trial for the Treatment of Schistosomiasis first appeared on PharmaShots.
